Effect of Pasteurella multocida toxin on physeal growth in young pigs. 1996

M R Ackermann, and K B Register, and J R Stabel, and S M Gwaltney, and T S Howe, and R B Rimler
USDA/Agricultural Research Service, National Animal Disease Center, Ames, IA 50010, USA.

OBJECTIVE To determine whether Pasteurella multocida toxin (PMT) affects growth of the proximal portion of the humerus of young pigs. METHODS 20 colostrum-deprived, cesarean-derived pigs. METHODS 5 groups (n = 4/group) of pigs were formed. Group-1 pigs received 0.1 ml of phosphate-buffered saline solution for 4 weeks; group-2 pigs received 0.05 microgram of PMT/kg of body weight at 14 and 21 days; group-3 pigs received 0.05 microgram of PMT/kg at 28 and 35 days; group-4 pigs received 0.1 microgram of PMT/kg at 14 and 21 days; and group-5 pigs received hyperimmune serum (from a sow given purified toxin) on days 13, 20, 27, and 34, and 0.1 microgram of PMT/kg on days 14, 21, 28, and 35. RESULTS All pigs given 0.1 microgram of PMT/kg without serum died or were euthanatized, as were 4 pigs given 0.05 microgram of PMT/kg. These pigs had increased serum interleukin 1 and 6 bioactivities. Pigs surviving 0.05 microgram of PMT had decreased weight gain, rough coat, marked atrophy of the ventral concha (as determined by turbinate perimeter ratios), and small stature. The surviving pigs also had reduced area and decreased proliferation indices in physeal chondrocytes on the basis of bromodeoxyuridine immunoreactivity. Control and serum-treated pigs gained weight, had no clinical effects, had similar physeal areas, and had higher cell proliferation indices. CONCLUSIONS PMT inhibits endochondral bone formation by reducing physeal area and chondrocyte proliferation in vivo. Hyperimmune serum neutralizes the effects of toxin on weight gain, clinical appearance, physeal area, and chondrocyte proliferation. CONCLUSIONS PMT may affect growth of the skeletal system. Antiserum to PMT is protective.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D007375 Interleukin-1 A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. IL-1,Lymphocyte-Activating Factor,Epidermal Cell Derived Thymocyte-Activating Factor,Interleukin I,Macrophage Cell Factor,T Helper Factor,Epidermal Cell Derived Thymocyte Activating Factor,Interleukin 1,Lymphocyte Activating Factor
D008297 Male Males
D001973 Bromodeoxyuridine A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors. BUdR,BrdU,Bromouracil Deoxyriboside,Broxuridine,5-Bromo-2'-deoxyuridine,5-Bromodeoxyuridine,NSC-38297,5 Bromo 2' deoxyuridine,5 Bromodeoxyuridine,Deoxyriboside, Bromouracil
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D005260 Female Females
D006132 Growth Plate The area between the EPIPHYSIS and the DIAPHYSIS within which bone growth occurs. Cartilage, Epiphyseal,Epiphyseal Cartilage,Epiphyseal Plate,Cartilages, Epiphyseal,Epiphyseal Cartilages,Epiphyseal Plates,Growth Plates,Plate, Epiphyseal,Plate, Growth,Plates, Epiphyseal,Plates, Growth
D006811 Humerus Bone in humans and primates extending from the SHOULDER JOINT to the ELBOW JOINT. Humeri,Greater Tubercle,Humeral Greater Tuberosity,Humeral Lesser Tuberosity,Lesser Tubercle,Olecranon Fossa,Olecranon Fossi,Greater Tubercles,Greater Tuberosities, Humeral,Greater Tuberosity, Humeral,Humeral Greater Tuberosities,Humeral Lesser Tuberosities,Lesser Tubercles,Lesser Tuberosities, Humeral,Lesser Tuberosity, Humeral,Tubercle, Greater,Tubercles, Greater
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001426 Bacterial Proteins Proteins found in any species of bacterium. Bacterial Gene Products,Bacterial Gene Proteins,Gene Products, Bacterial,Bacterial Gene Product,Bacterial Gene Protein,Bacterial Protein,Gene Product, Bacterial,Gene Protein, Bacterial,Gene Proteins, Bacterial,Protein, Bacterial,Proteins, Bacterial

Related Publications

M R Ackermann, and K B Register, and J R Stabel, and S M Gwaltney, and T S Howe, and R B Rimler
April 2009, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme,
M R Ackermann, and K B Register, and J R Stabel, and S M Gwaltney, and T S Howe, and R B Rimler
December 1966, Nihon saikingaku zasshi. Japanese journal of bacteriology,
M R Ackermann, and K B Register, and J R Stabel, and S M Gwaltney, and T S Howe, and R B Rimler
December 1992, Infection and immunity,
M R Ackermann, and K B Register, and J R Stabel, and S M Gwaltney, and T S Howe, and R B Rimler
September 1992, Australian veterinary journal,
M R Ackermann, and K B Register, and J R Stabel, and S M Gwaltney, and T S Howe, and R B Rimler
March 1987, Zentralblatt fur Veterinarmedizin. Reihe B. Journal of veterinary medicine. Series B,
M R Ackermann, and K B Register, and J R Stabel, and S M Gwaltney, and T S Howe, and R B Rimler
December 1996, The veterinary quarterly,
M R Ackermann, and K B Register, and J R Stabel, and S M Gwaltney, and T S Howe, and R B Rimler
August 1996, FEMS microbiology letters,
M R Ackermann, and K B Register, and J R Stabel, and S M Gwaltney, and T S Howe, and R B Rimler
January 2012, Current topics in microbiology and immunology,
M R Ackermann, and K B Register, and J R Stabel, and S M Gwaltney, and T S Howe, and R B Rimler
April 1990, The Veterinary record,
M R Ackermann, and K B Register, and J R Stabel, and S M Gwaltney, and T S Howe, and R B Rimler
April 2020, International journal of molecular sciences,
Copied contents to your clipboard!